CFM
BCRX icon

Capricorn Fund Managers’s BioCryst Pharmaceuticals BCRX Stock Holding History

Capricorn Fund Managers’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-202,900
Closed -$1.93M – 182
2026
Q1 		$1.93M Buy
+202,900
New +$1.58M 0.3% 74

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Capricorn Fund Managers's BCRX Position: Q2 2026 in Review

Capricorn Fund Managers sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 202,900 shares — an estimated $1.93M sold.

Capricorn Fund Managers first reported a position in BCRX in Q1 2026 and held it in 1 quarter. The position peaked at $1.93M in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Capricorn Fund Managers reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Capricorn Fund Managers sold 202,900 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.93M.
  • Capricorn Fund Managers first reported a position in BioCryst Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Capricorn Fund Managers's BioCryst Pharmaceuticals position peaked at $1.93M in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Capricorn Fund Managers's 13F filing for Q2 2026, filed 24 Jul 2026.